Clinicopathological and Immunohistochemical Features of Gastointestinal Stromal Tumors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to evaluate the clinicopathological features and immunohistochemical features of gastrointestinal stromal tumor (GIST), and specifically the expressions of platelet derived growth factor receptor A (PDGFRA), protein kinase C theta (PKC theta), discovered on GIST-1 (DOG-1), p16 and p27. Materials and Methods Total 118 patients who underwent surgical resection for GIST at our institution between Jan 1997 and Dec 2007 were retrospectively studied. Immunohistochemical staining for c-kit, PDGFRA, PKC-theta, DOG-1, p16 and p27 was performed on a tissue microarray of the 118 GIST. The clinicopathologic parameters, the disease-free survival (DFS) and the overall survival rate were analyzed along with immunohistochemistry. Results The immunohistochemical stains for c-kit, CD34, PKC-theta, PDGFRA, DOG-1, p16 and p27 were positive in 89.8%, 72.0%, 56.8%, 94.9%, 90.7%, 69.5% and 44.1% of the tumor samples, respectively. The immunohistochemical expression of c-kit was strongly correlated with PKC-theta (p=0.000), DOG-1 (p=0.000) and CD34 (p=0.002). The DFS rate was significantly decreased for the patients with peritoneal GIST, high risk GIST, ≥10 cm-sized GIST, ≥10mitoses/50 high power fields (HPFs) and p16 positivity (p=0.001, p=0.004, p=0.001, p=0.003 and p=0.028). GISTs ≥10 cm, epithelioid tumor cell type, and c-kit, and DOG-1 negativity were significantly associated with shorter period of overall survival (p=0.048, p=0.006, p=0.000 and p=0.000). Conclusion The expression of p16 and no expression of c-kit and DOG-1 in GISTs, as well as peritoneal tumor site, high risk group, large tumor size, epithelioid tumor cell type and numerous mitoses, may be potentially prognostic factors for predicting worse outcome for patients who suffer from GIST.
Abstract
Purpose The purpose of this study was to evaluate the clinicopathological features and immunohistochemical features of gastrointestinal stromal tumor (GIST), and specifically the expressions of platelet derived growth factor receptor A (PDGFRA), protein kinase C theta (PKC theta), discovered on GIST-1 (DOG-1), p16 and p27. Materials and Methods Total 118 patients who underwent surgical resection for GIST at our institution between Jan 1997 and Dec 2007 were retrospectively studied. Immunohistochemical staining for c-kit, PDGFRA, PKC-theta, DOG-1, p16 and p27 was performed on a tissue microarray of the 118 GIST. The clinicopathologic parameters, the disease-free survival (DFS) and the overall survival rate were analyzed along with immunohistochemistry. Results The immunohistochemical stains for c-kit, CD34, PKC-theta, PDGFRA, DOG-1, p16 and p27 were positive in 89.8%, 72.0%, 56.8%, 94.9%, 90.7%, 69.5% and 44.1% of the tumor samples, respectively. The immunohistochemical expression of c-kit was strongly correlated with PKC-theta (p=0.000), DOG-1 (p=0.000) and CD34 (p=0.002). The DFS rate was significantly decreased for the patients with peritoneal GIST, high risk GIST, ≥10 cm-sized GIST, ≥10mitoses/50 high power fields (HPFs) and p16 positivity (p=0.001, p=0.004, p=0.001, p=0.003 and p=0.028). GISTs ≥10 cm, epithelioid tumor cell type, and c-kit, and DOG-1 negativity were significantly associated with shorter period of overall survival (p=0.048, p=0.006, p=0.000 and p=0.000). Conclusion The expression of p16 and no expression of c-kit and DOG-1 in GISTs, as well as peritoneal tumor site, high risk group, large tumor size, epithelioid tumor cell type and numerous mitoses, may be potentially prognostic factors for predicting worse outcome for patients who suffer from GIST.
참고문헌 (24)
- Connolly E, "Gastrointestinal stromal tumours", Br J Surg, 90, pp.1178~1186 (2003)
- Fletcher C, "Diagnosis of gastrointestinal stromal tumors: a consensus approach", Int J Surg Pathol, 10, pp.81~ (2002)
- Miettinen M, "Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis", Virchows Arch, 438, pp.1~12 (2001)
- Hirota S, "Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors", Science, 279, pp.577~580 (1998)
- Motegi A, "PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors", Pathol Int, 55, pp.106~112 (2005)
- Sevinc A, "The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective", Onkologie, 30, pp.645~648 (2007)
- Chompret A, "PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor", Gastroenterology, 126, pp.318~321 (2004)
- West RB, "The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status", Am J Pathol, 165, pp.107~113 (2004)
- Pidhorecky I, "Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management", Ann Surg Oncol, 7, pp.705~712 (2000)
- Sircar K, "Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors", Am J Surg Pathol, 23, pp.377~389 (1999)
- Rabin I, "Gastrointestinal stromal tumors: a 19 year experience", Isr Med Assoc J, 11, pp.98~102 (2009)
- Liu FY, "Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor", World J Gastroenterol, 12, pp.4161~4165 (2006)
- Kim KM, "PKCtheta expression in gastrointestinal stromal tumor", Mod Pathol, 19, pp.1480~1486 (2006)
- Isaac JC, "A c-kit-negative gastrointestinal stromal tumor with a platelet-derived growth factor receptor alpha mutation", Appl Immunohistochem Mol Morphol, 14, pp.52~56 (2006)
- Miettinen M, "Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis", Arch Pathol Lab Med, 130, pp.1466~1478 (2006)
- Fletcher JA, "KIT mutations in GIST", Curr Opin Genet Dev, 17, pp.3~7 (2007)
- Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
- Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
- Joensuu H, "Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec)", Med Klin, 97, pp.28~30 (2002)
- Kim T, "Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors", Clin Cancer Res, 10, pp.3076~ (2004)
- Huang HY, "Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria", Ann Surg Oncol, 13, pp.1633~1644 (2006)
- Nemoto Y, "Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1", Pathol Int, 56, pp.724~731 (2006)
- Nakamura N, "Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade", Hum Pathol, 36, pp.828~837 (2005)
- Schmieder M, "p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome", Neoplasia, 10, pp.1154~1162 (2008)